SouthernWorldwide.com – A novel oral medication for pancreatic cancer is showing significant promise in its initial stages of testing, potentially altering the landscape of treatment for this aggressive disease.
The drug, named daraxonrasib, is a daily pill formulated to inhibit cancer signaling pathways associated with the RAS gene. It has recently concluded an early-stage clinical trial, marking its first human testing phase, to meticulously assess both its safety profile and its efficacy in combating the disease.
This pivotal clinical trial, spearheaded by the Dana-Farber Cancer Institute and subsequently published in the esteemed New England Journal of Medicine, involved 168 patients diagnosed with advanced pancreatic cancer. A key characteristic of their tumors was the presence of mutations in the RAS gene. Importantly, all participants in this study had previously undergone at least one course of chemotherapy treatment.
The pharmacological design of daraxonrasib aims to obstruct multiple active cancer signals that are instrumental in promoting the growth and proliferation of tumor cells. This mechanism is particularly crucial given that an overwhelming majority, exceeding 90%, of pancreatic cancers exhibit these detrimental mutations, according to the researchers.
Current and older therapeutic agents designed to target RAS mutations are often limited in their application, as they typically only function effectively against specific, less common types of RAS mutations found in pancreatic cancer, such as KRAS mutations.
At a dosage of 300 milligrams, which is the intended dose for larger Phase 3 trials, approximately 30% of patients demonstrated a positive response to the drug. Furthermore, a substantial 90% of patients experienced either a shrinkage of their tumors or a halt in disease progression. These findings were highlighted by the researchers.
During the trial, several side effects were documented. The most frequently reported adverse events included skin rash, inflammation of the mouth, nausea, and diarrhea. These were generally manageable with supportive care measures.
Dr. Brian Wolpin, the lead investigator and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber, expressed optimism regarding the drug’s potential impact. He stated in a press release that this advancement could significantly reshape the future of cancer care.
“If supported by data from future clinical trials, daraxonrasib would be a targeted therapy relevant to nearly all patients with advanced pancreatic cancer,” Dr. Wolpin remarked, underscoring its broad applicability.
He further elaborated, “This trial provides the first published data showing the safety and broad activity of a RAS(ON) multi-selective inhibitor in pancreatic cancer. If it proves effective in larger clinical trials, it would signify a substantial shift in how this disease is treated.”
This development is particularly noteworthy considering the historical scarcity of “effective therapies” for pancreatic cancer, as pointed out by Dr. Wolpin. The disease has long been a formidable challenge with limited treatment options.
“The study also showed disease control in approximately 90% of patients with metastatic pancreatic cancer, which is extremely exciting,” he added, emphasizing the promising rate of disease stabilization.
Dr. Wolpin also noted that while side effects were common, the majority of patients were able to tolerate the treatment through supportive care measures. Crucially, very few patients had to discontinue the therapy due to adverse effects, indicating a manageable safety profile.
It is important to note that as this was a Phase 1/2 study, it does not “definitively prove” the superiority of daraxonrasib when directly compared to chemotherapy. This limitation is inherent in the early-stage nature of the trial.
“The study did not include a randomized control arm that directly compared daraxonrasib with chemotherapy,” Dr. Wolpin explained. “That being said, the results for daraxonrasib looked substantially better than what we have seen in prior clinical trials of chemotherapy in patients with previously treated metastatic pancreatic cancer.” This suggests a potentially superior efficacy even without a direct head-to-head comparison in this phase.
Additionally, the drug’s performance earlier in the disease progression remains an area for further investigation, as the trial primarily included patients who had already undergone prior treatments.
For individuals and families affected by pancreatic cancer, Dr. Wolpin highlighted that daraxonrasib represents “real momentum” towards developing more effective treatments. However, he cautioned that the drug is still investigational and does not currently represent a cure.
“Pancreatic cancer remains a challenging disease, and additional research is needed to determine how best to sequence or combine therapies to provide the most durable responses and cures,” he stated, emphasizing the ongoing need for research and development.
An independent expert, who was not involved in the study, expressed anticipation for the upcoming presentation of the RASolute 302 trial at the ASCO meeting. “We are anxiously awaiting the upcoming plenary presentation of RASolute 302 at the ASCO meeting later this month,” said the expert. “Greater than 90% of pancreatic cancers have activation of kRAS, which is a major factor in the development and progression of these cancers.” This highlights the widespread relevance of targeting RAS mutations.
The expert further commented on the potential significance of the full dataset. “If the full dataset results that will be reported later this month confirm what was earlier released, I believe this will be one of the most important breakthroughs in all solid tumors. Doubling the survival time in pretreated patients is unprecedented.” This suggests the potential for a paradigm shift in cancer treatment.
The doctor added that the “magnitude of benefit” observed could “reshape the treatment landscape” and “establish a new standard of care” for pancreatic cancer patients. This indicates a potential for a significant change in clinical practice.
Read more : House lawmakers launch insider trading probe into Kalshi and Polymarket
“We will need to evaluate the full dataset for efficacy and safety,” the expert concluded. “I am more than cautiously optimistic, and I am truly excited for our patients and their families that suffer from this dreadful disease.” This sentiment reflects a hopeful outlook for the future of pancreatic cancer treatment.
